Zai Lab Limited Stock price

Equities

ZLAB

US98887Q1040

Pharmaceuticals

Real-time Estimate Cboe BZX 10:44:33 2024-03-28 am EDT 5-day change 1st Jan Change
16.16 USD -0.19% Intraday chart for Zai Lab Limited -7.07% -41.35%
Sales 2024 * 378M Sales 2025 * 614M Capitalization 1.6B
Net income 2024 * -307M Net income 2025 * -170M EV / Sales 2024 * 2.93 x
Net cash position 2024 * 491M Net cash position 2025 * 275M EV / Sales 2025 * 2.16 x
P/E ratio 2024 *
-5.1 x
P/E ratio 2025 *
-8.57 x
Employees 2,175
Yield 2024 *
-
Yield 2025 *
1.24%
Free-Float 97.22%
More Fundamentals * Assessed data
Dynamic Chart
Zai Lab Reports Lesser Loss in 2023 MT
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients MT
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer CI
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading MT
Asian Equities Traded in the US as American Depositary Receipts End Week Lower in Friday Trading MT
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate for Treatment of Solid Tumors CI
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading MT
Transcript : Zai Lab Limited, 2023 Earnings Call, Feb 28, 2024
Zai Lab's Loss Narrows in 2023 MT
Earnings Flash (ZLAB) ZAI LAB LIMITED Reports 2023 Revenue $266.7M MT
Zai Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zai Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Zai Lab Enters Into Loan Facility Deals MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
More news
1 day+1.50%
1 week-5.93%
Current month-22.83%
1 month-28.01%
3 months-37.85%
6 months-35.91%
Current year-40.76%
More quotes
1 week
15.69
Extreme 15.69
16.82
1 month
15.69
Extreme 15.69
22.19
Current year
15.69
Extreme 15.69
27.87
1 year
15.69
Extreme 15.69
40.42
3 years
15.69
Extreme 15.69
181.92
5 years
15.69
Extreme 15.69
193.54
10 years
14.29
Extreme 14.29
193.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 14-03-31
Director of Finance/CFO 56 21-08-31
President 54 22-07-31
Members of the board TitleAgeSince
Director/Board Member 81 16-12-31
Director/Board Member 73 16-12-31
Director/Board Member 66 18-12-31
More insiders
Date Price Change Volume
24-03-28 16 -1.14% 182 079
24-03-27 16.19 +1.50% 1,037,425
24-03-26 15.95 -1.85% 803,949
24-03-25 16.25 +0.43% 634,339
24-03-22 16.18 -6.20% 782,189

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.19 USD
Average target price
56.01 USD
Spread / Average Target
+245.93%
Consensus
  1. Stock
  2. Equities
  3. Stock Zai Lab Limited - Nasdaq